Histone deacetylase inhibitors
US7312247B2 · kind B2 · utility
8Cited by
100References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2001 |
| Grant date | Dec 25, 2007 |
| Priority date | — |
| Expiry date | Sep 1, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D307/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.